← Search

Excel · study · 2026

A randomized controlled trial of intravenous immunoglobulin compared with standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients (VIPAR)

Listed in NCBI GEO

The study included 30 kidney transplant recipients with chronic active antibody-mediated rejection (AMR), randomizing them (15 per arm) to receive prolonged (6-months), high dose (1gm/kg) IVIG, compared with standard of care, which currently is the optimization of baseline immunosuppression.

Description

We found that IVIG therapy reduced progression of our primary outcome measure of histological injury compared to the group receiving no-IVIG.

Histology was assessed using the CADI score across 4 biopsies taken at baseline, 3, 6 and 12-months. There was also relative stabilization of eGFR with IVIG compared to no-IVIG. An additional secondary outcome of note over extended follow-up (5-years) was improved patient survival in the IVIG group.

Read the rest (1 more)

Finally, intragraft mRNA expression was assessed using the Nanostring B-HOT panel and there were significant differences in expression between the two groups involving genes associated with B-cells, T-cells, natural killer cells and fibrosis.

Links

Where it is published

Documentation and papers

Topics

Stated by source
Homo sapiens · Other
From keywords
Life Sciences
Provenance · 1 source records, 7 field assertions
SourceKeyLast seenRaw
NCBI GEOGSE29575214 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[field].local:field:life-sciencesmapping · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[method].geo_series_type:othersource · NCBI GEOconnector:ncbi_geo@1.0.0/gdstype
concepts[organism].NCBITaxon:9606source · NCBI GEOconnector:ncbi_geo@1.0.0/taxon
descriptionsource · NCBI GEOconnector:ncbi_geo@1.0.0/summary
publication_datesource · NCBI GEOconnector:ncbi_geo@1.0.0
titlesource · NCBI GEOconnector:ncbi_geo@1.0.0/title